Johnathon Seth Parham1, Anne Carol Goldberg2. 1. Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, 660 South Euclid, Campus Box 8127, St. Louis, MO, 63110, USA. j.s.parham@wustl.edu. 2. Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, 660 South Euclid, Campus Box 8127, St. Louis, MO, 63110, USA.
Abstract
PURPOSE OF REVIEW: There have been recent developments of novel therapeutic agents for lipid lowering. This article reviews treatment concepts for two of the newest lipid-lowering medications. RECENT FINDINGS: Bempedoic acid inhibits adenosine citrate lyase, decreasing intracellular lipogenesis. This oral medication is a prodrug and requires activation by enzymes present in hepatocytes but absent in the skeletal muscle. Clinical trials demonstrated additive benefit with statin therapy, and it was well tolerated in statin-intolerant populations. Inclisiran uses RNA interference to prevent translation of PCSK9 mRNA. Due to its stability, it can be given as an injection every 6 months and produces consistent, durable, and potent cholesterol lowering. Bempedoic acid and inclisiran represent new avenues of treatment for the prevention and treatment of cardiovascular disease. This will allow for more comprehensive care by addressing challenges with medication adherence, such as adverse effects to prior medications as well as ease of dosing.
PURPOSE OF REVIEW: There have been recent developments of novel therapeutic agents for lipid lowering. This article reviews treatment concepts for two of the newest lipid-lowering medications. RECENT FINDINGS: Bempedoic acid inhibits adenosine citrate lyase, decreasing intracellular lipogenesis. This oral medication is a prodrug and requires activation by enzymes present in hepatocytes but absent in the skeletal muscle. Clinical trials demonstrated additive benefit with statin therapy, and it was well tolerated in statin-intolerant populations. Inclisiran uses RNA interference to prevent translation of PCSK9 mRNA. Due to its stability, it can be given as an injection every 6 months and produces consistent, durable, and potent cholesterol lowering. Bempedoic acid and inclisiran represent new avenues of treatment for the prevention and treatment of cardiovascular disease. This will allow for more comprehensive care by addressing challenges with medication adherence, such as adverse effects to prior medications as well as ease of dosing.
Authors: Emelia J Benjamin; Salim S Virani; Clifton W Callaway; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Stephanie E Chiuve; Mary Cushman; Francesca N Delling; Rajat Deo; Sarah D de Ferranti; Jane F Ferguson; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Pamela L Lutsey; Jason S Mackey; David B Matchar; Kunihiro Matsushita; Michael E Mussolino; Khurram Nasir; Martin O'Flaherty; Latha P Palaniappan; Ambarish Pandey; Dilip K Pandey; Mathew J Reeves; Matthew D Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Uchechukwu K A Sampson; Gary M Satou; Svati H Shah; Nicole L Spartano; David L Tirschwell; Connie W Tsao; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2018-01-31 Impact factor: 29.690
Authors: Maria J Gutierrez; Noah L Rosenberg; Diane E Macdougall; Jeffrey C Hanselman; Janice R Margulies; Poul Strange; Mark A Milad; Scott J McBride; Roger S Newton Journal: Arterioscler Thromb Vasc Biol Date: 2014-01-02 Impact factor: 8.311
Authors: Paul D Thompson; John Rubino; Matthew J Janik; Diane E MacDougall; Scott J McBride; Janice R Margulies; Roger S Newton Journal: J Clin Lipidol Date: 2015-03-19 Impact factor: 4.766
Authors: Kausik K Ray; Bart Molemans; W Marieke Schoonen; Periklis Giovas; Sarah Bray; Gaia Kiru; Jennifer Murphy; Maciej Banach; Stefano De Servi; Dan Gaita; Ioanna Gouni-Berthold; G Kees Hovingh; Jacek J Jozwiak; J Wouter Jukema; Robert Gabor Kiss; Serge Kownator; Helle K Iversen; Vincent Maher; Luis Masana; Alexander Parkhomenko; André Peeters; Piers Clifford; Katarina Raslova; Peter Siostrzonek; Stefano Romeo; Dimitrios Tousoulis; Charalambos Vlachopoulos; Michal Vrablik; Alberico L Catapano; Neil R Poulter Journal: Eur J Prev Cardiol Date: 2021-09-20 Impact factor: 7.804
Authors: Stephen L Pinkosky; Roger S Newton; Emily A Day; Rebecca J Ford; Sarka Lhotak; Richard C Austin; Carolyn M Birch; Brennan K Smith; Sergey Filippov; Pieter H E Groot; Gregory R Steinberg; Narendra D Lalwani Journal: Nat Commun Date: 2016-11-28 Impact factor: 14.919
Authors: Seth J Baum; Peter P Toth; James A Underberg; Paul Jellinger; Joyce Ross; Katherine Wilemon Journal: Clin Cardiol Date: 2017-03-22 Impact factor: 2.882